Ağaoğlu Zahid, Tanacan Atakan, Haksever Murat, Coşkun Hakan, İpek Göksun, Denizli Ramazan, Kara Özgür, Şahin Dilek
Ankara City Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey.
Turk J Obstet Gynecol. 2024 Dec 12;21(4):273-279. doi: 10.4274/tjod.galenos.2024.88886.
To evaluate the indications and methods of termination of pregnancy (TOP) and to identify maternal complications that occur during TOP.
This retrospective study was conducted at a single tertiary center with a total of 231 patients who underwent TOP from April 2019 to March 2023. The patients were divided into two groups based on gestational age at the time of TOP and the presence of complications. Group 1 consisted of patients with a gestational age of 11-22+6 weeks (n=196), while Group 2 comprised patients with a gestational age of 23-30 weeks (n=35). Additionally, the patients were categorized based on complications into those with complications (n=63) and those without complications (n=168). The TOP protocol involves misoprostol, a uterine balloon, a combination of misoprostol and balloon, or oxytocin. Procedure-related complications included the following: Rehospitalization, rest placenta, infection, uterine rupture, blood transfusion, and repeated manual vacuum curettage.
The median gestational age at TOP was 18.0±3.3 weeks for women without complications and 19.5±5.1 weeks for those with complications, it was 19.5±5.1 weeks (p=0.037). In the group with complications, the combined misoprostol-balloon method was used significantly more frequently, and the rate of previous cesarean sections was higher (p<0.05). The induction time was longer in the oxytocin group (p<0.05). The misoprostol-balloon combination group had the highest rate of uterine rupture (p<0.05).
TOP during advanced gestation is associated with increased rates of maternal complications, such as increased transfusion, uterine rupture, and hysterotomy. Higher gestational age and previous uterine surgery are the main causes of TOP-related maternal complications.
评估终止妊娠(TOP)的指征和方法,并确定TOP期间发生的母体并发症。
本回顾性研究在一家单一的三级中心进行,共有231例患者在2019年4月至2023年3月期间接受了TOP。根据TOP时的孕周和并发症情况将患者分为两组。第1组包括孕周为11 - 22 + 6周的患者(n = 196),而第2组包括孕周为23 - 30周的患者(n = 35)。此外,根据并发症情况将患者分为有并发症组(n = 63)和无并发症组(n = 168)。TOP方案包括米索前列醇、子宫球囊、米索前列醇与球囊联合使用或缩宫素。与手术相关的并发症包括以下几种:再次住院、胎盘残留、感染、子宫破裂、输血以及重复人工负压刮宫术。
无并发症女性TOP时的中位孕周为18.0±3.3周,有并发症女性为19.5±5.1周(p = 0.037)。在有并发症的组中,米索前列醇 - 球囊联合方法的使用频率显著更高,且既往剖宫产率更高(p < 0.05)。缩宫素组的引产时间更长(p < 0.05)。米索前列醇 - 球囊联合组的子宫破裂率最高(p < 0.05)。
晚期妊娠期间的TOP与母体并发症发生率增加相关,如输血增加、子宫破裂和子宫切开术。较高的孕周和既往子宫手术是TOP相关母体并发症的主要原因。